O6-MGMT levels and methylation status of the gene’s promotor region (epigenetic regulation) are useful predictors for the response to alkylating agents in gliomas [29] and B-cell lymphoma [30]. This evidence concerns the gene MGMT and B-cell non-Hodgkin lymphoma.